Harvard Bioscience Inc (NASDAQ:HBIO) traded at $0.41 at close of the session on Monday, June 02 and made a downward move of -13.19% on its previous day’s price.
Harvard Bioscience Inc has a market cap of $17.92 million and is expected to release its quarterly earnings report in July.
On the other hand, looking at the outlook for the HBIO stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 100% Sell.
Based on estimates by 1 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Harvard Bioscience Inc (HBIO) stock as a Hold, while 1 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 12.89% off its SMA20 and -2.21% from its 50-day simple moving average. The RSI (14) is pointing at 50.54 while the volatility over the past week is 56.52% and jumps to 23.02% over the past one month. The beta value is 1.56, while the average true range (ATR) is currently pointing at 0.11. The average price target for the stock over the next 12 months is $7, with the estimates having a low of $7 and a high of $7. These price ends are -1607.32% and -1607.32% off the current price level respectively, although investors could be excited at the prospect of a -1607.32% if the HBIO share price touches on the median price of $7.
